オプションチェーンは、BUFAB HLDG AB by BUFAB HLDG ABの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、BUFAB HLDG AB by BUFAB HLDG ABの市場センチメントを評価します。.

BUFAB HLDG AB by BUFAB HLDG AB (OTC:BFAAF) 株価情報, オプションチェーン

BUFAB HLDG AB by BUFAB HLDG AB

News

COST

Costco Earlier Reported Net Sales Of $20.03B For The Retail Month Of Oct., Up 7.2% YoY

Epsilon Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPSN#NASDAQ">EPSN</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.04 by 50 percent. This is unchanged from the same period last year. The company reported quarterly sales of $7.29 million which beat the analyst consensus estimate of $6.90 million by 5.62 percent. This is a 15.48 percent increase over sales of $6.31 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

EPSN

Epsilon Energy Q3 EPS $0.02 Misses $0.04 Estimate, Sales $7.29M Beat $6.90M Estimate

Vista Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTO#NYSE">VSTO</a>) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $0.95 by 8.42 percent. The company reported quarterly sales of $665.915 million which missed the analyst consensus estimate of $666.619 million by 0.11 percent. This is a 1.61 percent decrease over sales of $676.808 million the same period last year.

VSTO

Vista Outdoor Q2 2025 Adj. EPS $1.03 Beats $0.95 Estimate, Sales $665.915M Miss $666.619M Estimate

Aeva Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NYSE">AEVA</a>) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.59) by 6.78 percent. This is a 12.7 percent increase over losses of $(0.63) per share from the same period last year. The company reported quarterly sales of $2.250 million which beat the analyst consensus estimate of $2.100 million by 7.14 percent. This is a 177.78 percent increase over sales of $810.000 thousand the same period last year.

AEVA

Aeva Technologies Q3 2024 Adj. EPS $(0.55) Beats $(0.59) Estimate, Sales $2.250M Beat $2.100M Estimate

CrossAmerica Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAPL#NYSE">CAPL</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.25 by 8 percent. The company reported quarterly sales of $1.079 billion which missed the analyst consensus estimate of $1.284 billion by 15.95 percent. This is a 10.83 percent decrease over sales of $1.210 billion the same period last year.

CAPL

CrossAmerica Partners Q3 2024 GAAP EPS $0.27 Beats $0.25 Estimate, Sales $1.079B Miss $1.284B Estimate

EnLink Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENLC#NYSE">ENLC</a>) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.13 by 123.08 percent. This is a 130 percent decrease over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $1.61 billion which missed the analyst consensus estimate of $1.74 billion by 7.56 percent. This is a 7.88 percent decrease over sales of $1.75 billion the same period last year.

ENLC

EnLink Midstream Q3 EPS $(0.03) Misses $0.13 Estimate, Sales $1.61B Miss $1.74B Estimate

Riley Exploration Permian (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/REPX#AMEX">REPX</a>) reported quarterly earnings of $1.49 per share which missed the analyst consensus estimate of $1.57 by 5.1 percent. The company reported quarterly sales of $102.339 million which missed the analyst consensus estimate of $103.638 million by 1.25 percent. This is a 5.50 percent decrease over sales of $108.294 million the same period last year.

REPX

Riley Exploration Permian Q3 2024 Adj. EPS $1.49 Misses $1.57 Estimate, Sales $102.339M Miss $103.638M Estimate

Applovin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares are ripping higher in Wednesday&#8217;s after-hours session on the heels of the company&#8217;s third-quarter financial results. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/24/11/b41786448/applovin-announces-third-quarter-2024-financial-results">rundown of the report</a>.
<ul>
<li>Q3 Revenue: $1.2 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $1.13 billion</li>
</ul>
<ul>
<li>Q3 EPS: $1.25, versus estimates of 94 cents</li>
</ul>
Total revenue was up 39% year-over-year. Software platform revenue increased 66% year-over-year, while Apps revenue grew 1%. Cash flow from operations was $551 million in the quarter and free cash flow came in at $545 million. Applovin ended the quarter with $568 million in cash and cash equivalents. 
Applovin&#8217;s board increased the company&#8217;s share repurchase program by $2 billion. The company said it now has $2.3 billion remaining under the buyback. The company expects to fund future repurchases with free cash flow.
&#8220;We had another fantastic quarter in the third quarter. Our AXON models continue to improve through self-learning and, more importantly this quarter, from technology enhancements by our engineering team. As we continue to improve our models our advertising partners are able to successfully spend at a greater scale,&#8221; the company said in a letter to shareholders.
Outlook: Applovin expects fourth-quarter revenue to be in the range of $1.24 billion to $1.26 billion. The company expects fourth-quarter adjusted EBITDA to be in the range of $740 million to $760 million.
Management is currently discussing the quarter on a conference call that kicked off at 5 p.m. ET.
APP Price Action: <a href="http://benzinga.com/quote/app">Applovin shares</a> were up 28.15% after hours at $216 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: • <a href="https://www.benzinga.com/news/earnings/24/11/41789162/lyft-stock-drives-higher-after-better-than-expected-q3-results">Lyft Stock Drives Higher After Better-Than-Expected Q3 Results</a>
Photo: Pixabay.

Guidance

After-Hours Center

Movers

Applovin Stock Soars After Q3 Earnings Report: Revenue Beat, EPS Beat, Strong Software Platform Growth

Biotech

General

CPIX

Cumberland Pharmaceuticals Receives FDA Orphan Drug, Rare Pediatric Disease Designations For New Treatment Of Duchenne Muscular Dystrophy

Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. This is a 50 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $9.208 million which beat the analyst consensus estimate of $8.110 million by 13.53 percent. This is a 81.26 percent increase over sales of $5.080 million the same period last year.

Myomo Q3 2024 GAAP EPS $(0.03) Beats $(0.04) Estimate, Sales $9.208M Beat $8.110M Estimate

ARDT

Ardent Health Raises FY24 Revenue To $5.8B-$5.875B From $5.75B-$5.9B; Updates Diluted EPS To $1.18-$1.32 From $1.23-$1.37

SENEA

Seneca Foods Q2 Revenue $425.5M Up From $407.5M YoY

Full House Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLL#NASDAQ">FLL</a>) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.10) by 140 percent. This is a 284.62 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $75.687 million which missed the analyst consensus estimate of $78.918 million by 4.09 percent. This is a 5.79 percent increase over sales of $71.543 million the same period last year.

Full House Resorts Q3 2024 GAAP EPS $(0.24) Misses $(0.10) Estimate, Sales $75.687M Miss $78.918M Estimate

Select Medical Holdings Corporation Declares Special Stock Distribution To Spin-Off Concentra; Estimates Stockholders Will Receive Approximately 0.806971 Shares Of Concentra's Common Stock For Every Share Of Select Medical's Common Stock Held As Of The Close Of Business On The Record Date

Algoma Steel Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTL#NASDAQ">ASTL</a>) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.27) by 166.67 percent. This is a 500 percent decrease over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $440.03 million which missed the analyst consensus estimate of $568.90 million by 22.65 percent. This is a 19.42 percent decrease over sales of $546.10 million the same period last year.

ASTL

Algoma Steel Gr Q2 EPS $(0.72) Misses $(0.27) Estimate, Sales $440.03M Miss $568.90M Estimate

Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.20 by 10 percent. This is a 4.35 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $34.175 million which missed the analyst consensus estimate of $34.645 million by 1.36 percent. This is a 3.70 percent decrease over sales of $35.487 million the same period last year.

GMRE

Global Medical REIT Q3 2024 FFO $0.22 Beats $0.20 Estimate, Sales $34.175M Miss $34.645M Estimate

The company remains on track for a topline Phase 1 data readout by the end of the year.

SABS

SAB BIO Says Co Completed Phase 1 Enrollment For SAB-142 With No Observation Of Serum Sickness

SAB BIO Q3 2024 Cash, Cash Equivalents Available $30.4M-$56.6M

Granite Point Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPMT#NYSE">GPMT</a>) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.82) by 8.54 percent. The company reported quarterly sales of $7.658 million which missed the analyst consensus estimate of $10.598 million by 27.74 percent. This is a 61.55 percent decrease over sales of $19.915 million the same period last year.

GPMT

Granite Point Mortgage Q3 2024 Adj. EPS $(0.75) Beats $(0.82) Estimate, Sales $7.658M Miss $10.598M Estimate

Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 62.5 percent decrease over losses of $(0.08) per share from the same period last year.

Comments

BUFAB HLDG AB by BUFAB HLDG AB

BUFAB HLDG AB by BUFAB HLDG AB (BFAAF) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル